MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

计划入组 15 人 · 首次发布于 2019 年 5 月 1 日

CART-19 Cells for R/R B-cell Lymphoma

计划入组 20 人 · 首次发布于 2018 年 1 月 5 日

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

计划入组 8 人 · 首次发布于 2023 年 4 月 10 日

Tisagenlecleucel(Kymriah)

Rx

CAR T-cell therapy (relapsed/refractory B-ALL)

Epcoritamab(Epkinly, Tepkinly)

Rx

Karyopharm Therapeutics

United States

CARGO Therapeutics

United States

Tres-Or Resources Ltd

FDA Expands Adcetris Approval for Relapsed Large B-Cell Lymphoma Treatment

Three-Year Data Shows Sustained Benefits of CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Chugai Receives World-First Approval for Lunsumio-Polivy Combination in Relapsed Large B-Cell Lymphoma